Arkolith/Insider Trading/ONCT/Form 4

Breitmeyer James B

Chief Executive Officer, DirectorOncternal Therapeutics, Inc. (ONCT) · full profile →Form 4 · filed Feb 15, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
0 non-derivative · 2 derivative

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 14, 2024Grant(A)28K—$028K
Feb 14, 2024Grant(A)6K—$06K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-24-003413) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML